Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Идёт Фаза III Россия Набор открыт

4-MUST; Placebo

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Patients With Chronic Cholecystitis and Biliary Tract Dyskinesia

Номер протоколаGIB-03-04-2025
ФазаФаза III
Участников по плану — во всех странах исследования300
Сроки12.12.2025 — 31.12.2027
Начало: 12 декабря 2025Окончание: 31 декабря 2027
Пройдено 46% планового срока

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07595003/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование идёт, в реестре указано, что набор участников открыт.
  • Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 300 чел. во всех странах исследования.
  • Центров в реестре: 9 в 5 городах. Список — ниже на странице.
  • Плановое окончание — 12.2027.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–70 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 45 · невключение: 12

Критерии включения

  • Males and females aged 18-70 years.
  • Diagnosed with chronic cholecystitis (K81.1) and/or dyskinesia of the cystic duct or gallbladder (K82.8) prior to enrollment; diagnosis supported by clinical history of exacerbations and remissions and/or imaging/laboratory findings.
  • Upper abdominal pain or discomfort attributable to gallbladder or biliary tract dysfunction (per investigator assessment), accompanied by ≥1 of the following: heartburn, belching, nausea, abdominal bloating, borborygmi (stomach rumbling), flatulence, constipation, or diarrhea.
  • Maximum severity of pain/discomfort in the upper abdomen over the past week is 40 mm or more on the VAS (Visual Analog Scale).
  • Severity of gastrointestinal symptoms according to the GSRS (Gastrointestinal Symptom Rating Scale) questionnaire is at least 30 points.
  • The total bilirubin level does not exceed 2 times the upper limit of normal (no more than 42 μmol/L).
  • Women who are either sexually abstinent or using effective contraception methods (e.g. intrauterine devices, contraceptive patches, long-acting injectable contraceptives, or double barrier methods) for at least 8 weeks before and 3 weeks after the end of the study, with a confirmed negative pregnancy test, as well as women with documented infertility or non-childbearing status (e.g. hysterectomy, tubal ligation, infertility or menopause for more than 1 year) or men using barrier contraceptives throughout the study and for 3 weeks after its completion, or men unable to conceive (documented conditions: vasectomy, infertility).
  • Signed and dated informed consent from.
  • Non-inclusion Criteria:
  • Gastric or duodenal ulcer, erosive gastroesophageal reflux disease (GERD), or other inflammatory/erosive gastrointestinal diseases in the acute stage, unless stable remission for ≥ 1 year since the last exacerbation.
  • Indication for surgical or endoscopic intervention due to exacerbation of chronic cholecystitis or complications of biliary tract dyskinesia.
  • Toxic megacolon.
  • Paralytic ileus.
  • Gilbert's syndrome.
  • Choledocholithiasis (or a high risk of its development, as determined by the investigator);
  • Impaired bile outflow due to adhesions in the abdominal cavity.Abdominal adhesion disease.
  • Irritable bowel syndrome, non-specific ulcerative colitis, Crohn's disease.
  • Gastrointestinal malignancy (including history of) or suspected gastrointestinal malignancy (e.g., blood in stool, unexplained weight loss, fever, anemia).
  • Any other oncological diseases known at the time of screening, or suspicion thereof.
  • History of gastrointestinal surgery, including cholecystectomy or endoscopic sphincterotomy (appendectomy excluded).
  • Use of prohibited therapy medications within 3 days prior to randomization.
  • History of mental illnesses.
  • Chronic heart failure IIb-III stages and/or III-IV functional classes according to NYHA, angina pectoris III-IV functional classes.
  • Chronic kidney disease stage IIIa-V (according to NKF/KDOQI, 2006).
  • History of or current hepatic impairment; or liver test abnormalities: AST, ALT, ALP, or GGT >3 above the upper limit of normal (ULN); total bilirubin >2 ULN or clinical jaundice.
  • HIV, syphilis, viral hepatitis B or C, including in history.
  • Lactose intolerance, lactase deficiency, and glucose-galactose malabsorption syndrome.
  • Liver cirrhosis.
  • Hypersensitivity to the active ingridient or any of the excipients of the drug 4-MUST.
  • Severe, decompensated, or unstable somatic conditions that are life-threatening, worsen prognosis, or preclude safe study participation.
  • Diabetes mellitus in a state of subcompensation and decompensation.
  • Systemic connective tissue diseases.
  • Autoimmune diseases.
  • Indication for hemodialysis procedures.
  • Epilepsy or seizures of unclear etiology, including in history.
  • Alcoholism, substance abuse or drug addiction, including in history.
  • Uncorrected electrolyte disturbances.
  • QTcF interval on a 12-lead electrocardiogram (ECG) ≥430 ms in men and ≥450 ms in women.
  • Episodes of constipation during the last 3 months that required the prescription of drug therapy.
  • History of surgery within 6 month prior to screening.
  • Women during pregnancy or lactation; women planning to become pregnant within the next 6 months.
  • Patients who require prohibited concomitant therapy within this study framework.
  • Participation in another clinical trial within the last 3 months prior to the screening visit date.
  • Unwillingness or inability to comply with study procedures and protocol requirements..
  • Other conditions that, in the investigator's judgement, may preclude the patient's participation in the study.

Критерии невключения

  • Incorrect enrollment of a patient in the study (failure to meet inclusion/exclusion criteria at the time of randomization).
  • Lack of Efficacy. Study treatment will be discontinued if no clinical improvement is observed by Visit 3 (Day 15 ± 1), defined as persistence or worsening of upper abdominal pain/discomfort (assessed by Visual Analog Scale \[VAS\]) compared to baseline. Upon discontinuation, alternative therapy will be initiated at the investigator's discretion.
  • Patient non-compliance (a compliant patient is defined as one who has taken at least 202 and no more than 303 tablets).
  • Requirement for prohibited concomitant therapy.
  • Use of Duspatalin® (INN: mebeverine) for more than 3 consecutive days or for more than 5 days in total throughout the study.
  • If the investigator judges that comtinued participation in the study would harm the patient.
  • Pregnancy or the need for breastfeeding.
  • Major protocol deviation by the subject with respect to procedures outlined in the Informed Consent Form (ICF).
  • Withdrawal of informed consent by the subject (decision to discontinue study participation).
  • Lost to follow-up: Inability to contact the subject after ≥3 documented attempts via mobile phone, landline (if applicable), and designated emergency contact.
  • Emergence during the study of any diseases or conditions that worsen the patient's prognosis, making it impossible for the patient to continue participating in this clinical trial.
  • Any other reasons, including administrative issues, that in the investigator's judgement may interfere with subject's ability to comlete the study.

Источник: ClinicalTrials.gov, NCT07595003 · запись обновлена в реестре 19 мая 2026.

Дизайн и результаты

ДизайнРандомизированное, двойное слепое, параллельные группы; цель — лечение
Участников по плану (все страны)300
Результатыбудут после окончания
Что измеряют — первичные конечные точки (1), вторичных — 65
  • Mean reduction in the severity of pain/discomfort in the upper abdomen on the VAS by day 29 compared to baseline — Day 29 ± 1

Цель исследования

The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.

Где проходит

9 центров в 5 городах

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07595003 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, набор участников, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.